British drugmaker AstraZeneca plans to spend $200 million over the next three years, expanding its manufacturing facility in Frederick, Md., and hiring an additional 300 workers at the site, executives said.
The decision further cements Gaithersburg-based MedImmune, an AstraZeneca company, as the crown jewel of Maryland’s life sciences industry.
Nestled in a quiet industrial park in Redmond, Washington, not too far from the Microsoft headquarters, is a small biotech start-up with both an interesting technology they are bringing to market, as well as a capital partner that suggests some ways in which global biotech research, venture capital and commercialization are going to change.
The Federal Laboratory Consortium for Technology Transfer (FLC), a nationwide network of federal laboratories that cultivates best-practice strategies for advancing technology transfer (T2) from the laboratory to the marketplace, today announced the launch of FLCBusiness, an interactive business resource tool.
As the sound of pile driver at the Edward St. John’s Learning and Teaching Center construction site boomed across Campus Drive, officials broke ground Friday morning on another project: a bioengineering building aimed at forwarding research in a relatively new field.
Britain’s GlaxoSmithKline (GSK.L) has asked its shareholders to vote at a meeting on Dec. 18 on its proposed major deal with Switzerland’s Novartis (NOVN.VX), which will see the two pharmaceutical group trade more than $20 billion of assets.
Digital technologies such as electronic medical records, mobile devices, and analytics offer the potential to transform health care. Whether it’s a patient using her smartphone to better manage her diabetes, a provider monitoring a patient for arrhythmia remotely, or an electronic health-record system alerting a clinician of a potential drug allergy, digital technologies can create meaningful value for patients and practitioners alike. Yet there are significant barriers to the development and adoption of such technologies that academic medical centers are uniquely positioned to overcome.
Myron M. Levine, MD, DTPH, director of the University of Maryland School of Medicine Center for Vaccine Development (CVD), and Dean E. Albert Reece, MD, PhD, MBA, announced today the start of a clinical trial in Baltimore to evaluate different dosage levels of a promising experimental Ebola vaccine developed by the Vaccine Research Center (VRC) of the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, and GlaxoSmithKline (GSK
British drugmaker AstraZeneca is doubling down on Maryland, spending $200 million to expand its Frederick manufacturing facility a year after shifting hundreds of out-of-state jobs to Montgomery County.
There are presently massive shifts occurring in the competitive global landscape of health, and particularly in the life sciences. As we approach 2015, it is imperative that leaders in the health space understand the trends and shifts happening around them, not only in the US, but also in international markets, cities and service lines.
Drug giant AstraZeneca will expand its biologics manufacturing center in Frederick and add hundreds of jobs to its operations there.
The drug giant will spend more than $200 million to increase production capacity. MedImmune, AstraZeneca’s biologics research and development arm, has more than 120 drugs in its research pipeline, including more than 30 in clinical development. AstraZeneca says the expansion will support its research.
